3. FEJEZET | HIVATKOZÁSOK


  1. Kitchen S, McCraw A, Echenagucia M. Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual, 2nd ed. Montreal, Canada: World Federation of Hemophilia; 2010. https://www1. wfh.org/publications/files/pdf-1283.pdf. Hozzáférés: 2019. szeptember 12.
  2. Venema CL, Schutgens REG, Fischer K. Pathophysiological mechanisms of endogenous FVIII release following strenuous exercise in non- severe haemophilia: a review. Thromb Haemost. 2017;117(12):2237-2242.
  3. Austin AW, Wirtz PH, Patterson SM, Stutz M, von Kanel R. Stress-induced alterations in coagulation: assessment of a new hemoconcentration correction technique. Ps ychosom Med. 2012;74(3):288-295.
  4. Delbruck C, Miesbach W. The course of von Willebrand factor and factor VIII activity in patients with von Willebrand disease during pregnancy. Acta Haematol. 2019;142(2):71-78.
  5. Clinical and Laboratory Standards Institute. CLSIH21-A5 Collection, Transport, and Processing of Blood Specimens for Testing PlasmaBased Coagulation Assays and Molecular Hemostasis Assays, 5th ed. Vol. 28, No. 5. Wayne, PA: Clinical and Laboratory Standards Institute, 2008. https://clsi.org/media/1399/h21a5_sample.pdf. Hozzáférés: 2019. szeptember 12.
  6. Heil W, Grunewald R, Amend M, Heins M. Influence of time and temperature on coagulation analytes in stored plasma. Clin Chem Lab Med. 1998;36(7):459-462.
  7. Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost. 2012;38(6):576-585.
  8. Omidkhoda A, Tabatabaei MR, Atarodi K, Karimi K, Froushani AR, Pourfathollah AA. A comparative study of the effects of temperature, time and factor VIII assay type on factor VIII activity in cryoprecipitate in Iran. Blood Transfus. 2011;9(4):394-399.
  9. Feng L, Zhao Y, Zhao H, Shao Z. Effects of storage time and temperature on coagulation tests and factors in fresh plasma. Sci Rep. 2014;4:3868.
  10. Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost. 2012;38(6):565-575.
  11. Favaloro EJ, Soltani S, McDonald J. Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. A m J Clin Pathol. 2004;122(5):686-692.
  12. Espenhain Landgrebe L, Schlosser Mose L, Palarasah Y, Sidelmann JJ, Bladbjerg EM. The effects of sampling from a peripheral venous catheter compared to repeated venepunctures on markers of coagulation, inflammation, and endothelial function. Scand J Clin Lab Invest. 2019;79(8):584-589.
  13. Marlar RA, Potts RM, Marlar AA. Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values. Am J Clin Pathol. 2006;126(3):400-405.
  14. Siegel JE, Swami VK, Glenn P, Peterson P. Effect (or lack of it) of severe anemia on PT and APTT results. A m J Clin Pathol. 1998;110(1):106-110.
  15. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis. 2001;12(4):229-236.
  16. Woolley A, Golmard JL, Kitchen S. Effects of haemolysis, icterus and lipaemia on coagulation tests as performed on Stago STA- Compact- Max analyser. Int J Lab Hematol. 2016;38(4):375-388.
  17. Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. S emin Thromb Hemost. 2013;39(3):258-266.
  18. Laga AC, Cheves TA, Sweeney JD. The effect of specimen hemolysis on coagulation test results. Am J Clin Pathol. 2006;126(5):748-755.
  19. Clinical and Laboratory Standards Institute. CLSIH47-A2 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test, 2nd ed. Vol. 28, No. Wayne, PA: Clinical and Laboratory Standards Institute, 2008. https://clsi.org/media/1394/ h47a2_sample.pdf. Hozzáférés: 2019. szeptember 12.
  20. Girolami A, Scarparo P, Bonamigo E, Treleani M, Lombardi AM. Homozygous FVII deficiencies with different reactivity towards tissue thromboplastins of different origin. Hematology. 2012;17(6):350-354.
  21. Bowyer A, Smith J, Woolley AM, et al. The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal. Int J Lab Hematol. 2011;33(2):212-218.
  22. Jennings I, Kitchen DP, Kitchen S, Woods TA, Walker ID. Investigation of a prolonged APTT: different approaches taken by laboratories to achieve the same diagnosis. I nt J Lab Hematol. 2013;35(2):177-182.
  23. Bick RL. Laboratory evaluation of platelet dysfunction. Clin Lab Med. 1995;15(1):1-38.
  24. Rodgers RP, Le vin J. Bleeding time revisited. Blo od. 1992;79(9):2495-2497.
  25. Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia. 2015;21(4):550-557.
  26. Gomez K, Chitlur M, GEHEP panel. Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A. Thromb Haemost 2013;109(4):738-743.
  27. Kitchen S, Blakemore J, Friedman KD, et al. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays. J Thromb Haemost. 2016;14(4):757-764.
  28. Al-Samkari H, Croteau SE. Shifting landscape of hemophilia therapy: implications for current clinical laboratory coagulation assays. Am J Hematol. 2018;93(8):1082-1090.
  29. Gouws W, Botha E, Visser A. Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay. J Thromb Thrombolysis. 2014;37(2):210-215.
  30. Kusch M, Grundmann C, Keitel S, Konig H. Factor VIII assay mimicking in vivo coagulation conditions. Haemophilia. 2014;20(2):e16 4-e170.
  31. Bangham DR, Biggs R, Brozovic M, Denson KW, Skegg JL. A biological standard for measurement of blood coagulation factor VIII activity. Bull World Health Organ. 1971;45(3):337-351.
  32. Hubbard AR, Rigsby P, Barrowcliffe TW. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Thromb Haemost. 2001;85(4):634-638.
  33. Hubbard AR, Heath AB. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost. 2004;2(8):1380-1384.
  34. Hubbard AR, Rigsby P, Barrowcliffe TW. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586). Thromb Haemost. 2001;85(4):634-638.
  35. Tang N, Yin S. An easy method to eliminate the effect of lupus anticoagulants in the coagulation factor assay. Clin Lab. 2016;62(7):1363- 1365.
  36. Bonar R, Favaloro EJ, Mohammed S, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology. 2016;48(1):60-71.
  37. Lattes S, Appert-Flory A, Fischer F, Jambou D, Toulon P. Measurement of factor VIII activity using one-stage clotting assay: a calibration curve has not to be systematically included in each run. Haemophilia. 2011;17(1):139-142.
  38. Guy S, Sermon-Cadd AM, Shepherd FM, Kitchen S, Bowyer AE. A cost-effective approach to factor assay calibration using a truncated live calibration curve. Int J Lab Hematol. 2019;41(5):679-683.
  39. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol. 1994;87(4):846-848.
  40. Oldenburg J, Pavlova A. D iscrepancy between one-st age and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. H amostaseologie. 2010;30(4):207-211.
  41. Duncan EM, Rodgers SE, McRae SJ. Diagnostic testing for mild hemophilia A in patients with discrepant one-stage, two-stage, and chromogenic factor VIII: C assays. Semin Thromb Hemost. 2013;39(3):272-282.
  42. Moser KA, Adcock Funk DM. Chromogenic factor VIII activity assay. Am J Hematol. 2014;89(7):781-784.
  43. Bowyer AE, Van Veen JJ, Goodeve AC, Kitchen S, Makris M. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica. 2013;98(12):1980-1987.
  44. Pavlova A, Delev D, Pezeshkpoor B, Muller J, Oldenburg J. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one- stage and chromogenic factor VIII activity assays. Thromb Haemost. 2014;111(5):851-861.
  45. Trossaert M, Lienhart A, Nougier C, et al. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements. Haemophilia. 2014;20(4):550-558.
  46. Trossaert M, Boisseau P, Quemener A, et al. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost. 2011;9(3):524-530.
  47. Bowyer AE, Goodeve A, Liesner R, Mumford AD, Kitchen S, Makris M. p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it. Br J Haematol. 2011;154(5):618-625.
  48. Lyall H, Hill M, Westby J, Grimley C, Dolan G. Tyr346–>Cys mutation results in factor VIII: C assay discrepancy and a normal bleeding phenotype–is this mild haemophilia A? Haemophilia. 2008;14(1):78-80.
  49. Stufano F, Baronciani L, Peyvandi F. Diagnosis of von Willebrand Disease: Phenotypic Characterization. Treatment of Hemophilia Monograph No. 55. Montreal, Canada: World Federation of Hemophilia, 2017. https://elearning.wfh.org/resource/diagnosis-von- willebrand-disease-phenotypic-characterization Accessed February 24, 2020.
  50. Suzuki A, Suzuki N, Kanematsu T, et al. Performance evaluation of Revohem™ FVIII chromogenic and Revohem™ FIX chromogenic in the CS-5100 autoanalyser. Int J Lab Hematol. 2019;41(5):664-670.
  51. Horn C, Negrier C, Kalina U, Seifert W, Friedman KD. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost. 2019;17(1):138-148.
  52. Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially available one- stage clotting and chromogenic assay kits: a two-center study. J Thromb Haemost. 2016;14(7):1428-1435.
  53. Kihlberg K, Strandberg K, Rosen S, Ljung R, Astermark J. Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B. Haemophilia. 2017;23(4):620-627.
  54. Kershaw GW, Dissanayake K, Chen VM, Khoo TL. Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia. 2018;24(3):492-501.
  55. Bakhtiari K, Kamphuisen PW, Mancuso ME, et al. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients. Br J Haematol. 2013;162(6):827-835.
  56. Khanum F, Collins PW, Harris RL, Bowen DJ. Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay. Haemophilia. 2014;20(2):287-293.
  57. Gilmore R, Harmon S, Gannon C, Byrne M, O’Donnell JS, Jenkins PV. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia. 2010;16(4):671-674.
  58. Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost. 2017;43(3):331-337.
  59. Hubbard AR, Dodt J, Lee T, et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost. 2013;11(5):988-989.
  60. Gray E, Kitchen S, Bowyer A, et al. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2019;00:1-11.
  61. Pruthi RK. Laboratory monitoring of new hemostatic agents for hemophilia. Semin Hematol. 2016;53(1):28-34.
  62. St Ledger K, Feussner A, Kalina U, et al. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories. J Thromb Haemost. 2018;16(3):555-564.
  63. CSL Behring. AFSTYLA®, antihemophilic factor (recombinant), single chain lyophilized powder for solution for intravenous injection [U.S. prescribing information]. Lengnau, Switzerland: CSL Behring. Revised 12/2019.
  64. Bowyer A, Key N, Dalton D, Kitchen S, Makris M. The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate. Haemophilia. 2017;23(5):e469-e470.
  65. Collins P, Chalmers E, Chowdary P, et al. The use of enhanced halflife coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22(4):487-498.
  66. Church N, Leong L, Katterle Y, et al. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: results from an international laboratory study. Haemophilia. 2018;24(5):823-832.
  67. Kitchen S, Beckmann H, Katterle Y, Bruns S, Tseneklidou-Stoeter D, Maas Enriquez M. BAY 81-8973, a full-length recombinant factor VIII: results from an international comparative laboratory field study. Haemophilia. 2016;22(3):e192-e199.
  68. Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TA, Walker ID. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII. Haemophilia. 2016;22(5):806-812.
  69. Turecek PL, Romeder-Finger S, Apostol C, et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 2016;22(6):957-965.
  70. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia. 2011;17(4):695-702.
  71. Jacquemin M, Vodolazkaia A, Toelen J, et al. Measurement of B- domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors. Haemophilia. 2018;24(4):675-682.
  72. Cauchie M, Toelen J, Peerlinck K, Jacquemin M. Practical and cost-effective measurement of B-domain deleted and fulllength recombinant FVIII in the routine haemostasis laboratory. Haemophilia. 2013;19(3):e133-e138.
  73. Morfini M, Cinotti S, Bellatreccia A, et al. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost. 2003;1(11):2283-2289.
  74. Ingerslev J, Jankowski MA, Weston SB, Charles LA, ReFacto Field Study Participants. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr factor VIII: C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost. 2004;2(4):623-628.
  75. Santoro C, Iorio A, Ferrante F, et al. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia. 2009;15(3):779-787.
  76. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119(13):3031-3037.
  77. McCue J, Kshirsagar R, Selvitelli K, et al. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein. Biologicals. 2015;43(4):213-219.
  78. Sommer JM, Moore N, McGuffie-Valentine B, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014;20(2):294-300.
  79. Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TAL, Walker ID. Clotting and chromogenic factor VIII assay variability in postinfusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc). Int J Lab Hematol. 2019;41(2):176-183.
  80. Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017;23(3):458-465.
  81. Pickering W, Hansen M, Kjalke M, Ezban M. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP. J Thromb Haemost. 2016;14(8):1579-1587.
  82. Persson E, Foscolo T, Hansen M. Reagent-specific underestimation of turoctocog-α pegol (N8-GP) clotting activity owing to decelerated activation by thrombin. Res Pract Thromb Haemost. 2019;3(1):114-120.
  83. Ezban M, Hansen M, Kjalke M. An overview of turoctocog-α pegol (N8-GP; ESPEROCT®) assay performance: implications for postadministration monitoring. Haemophilia. 2020;26:156-163.
  84. Hegemann I, Koch K, Clausen WHO, Ezban M, Brand-Staufer B. Evaluation of N8-GP activity using a one-stage clotting assay: a single- center experience. Acta Haematol. 2019;1-5.
  85. Tiefenbacher S, Clausen WHO, Hansen M, Lutzhoft R, Ezban M. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories. Haemophilia. 2019;25(5):893-901.
  86. Gu JM, Ramsey P, Evans V, et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia. 2014;20(4):593-600.
  87. Bulla O, Poncet A, Alberio L, et al. Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study. Haemophilia. 2017;23(4):e3 35-e339.
  88. Weber A, Engelmaier A, Mohr G, Haindl S, Schwarz HP, Turecek PL. Selective functional activity measurement of a PEGylated protein with a modification-dependent activity assay. J Pharm Biomed Anal. 2017;132:207-214.
  89. Vanguru VR, Kershaw G, Konda M, Chen VM. Laboratory monitoring issues in recombinant porcine FVIII replacement in acquired haemophilia A. Haemophilia. 2018;24(2):e70-e74.
  90. Wilmot HV, Hogwood J, Gray E. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays. Haemophilia. 2014;20(6):891-897.
  91. Sommer JM, Buyue Y, Bardan S, et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost. 2014;112(5):932-940.
  92. Bowyer AE, Shepherd MF, Kitchen S, Maclean RM, Makris M. Measurement of extended half-life recombinant factor IX products in clinical practice. Int J Lab Hematol. 2019;41(2):e46-e49.
  93. Rosen P, Rosen S, Ezban M, Persson E. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost. 2016;14(7):1420-1427.
  94. Tiefenbacher S, Bohra R, Amiral J, et al. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J Thromb Haemost. 2017;15(10):1901-1912.
  95. Ezban M, Hermit MB, Persson E. FIXing postinfusion monitoring: assay experiences with N9-GP (nonacog beta pegol; Refixia®; Rebinyn®). Haemophilia. 2019;25(1):154-161.
  96. Blair HA. Emicizumab: a review in haemophilia A. Drugs. 2019;79(15):1697-1707.
  97. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463-2468.
  98. Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119(7):1084-1093.
  99. Jenkins PV, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment: a United Kingdom Haemophilia Centre Doctors’ Organisation[1]guideline.[1]Haemophilia. 2020;26:151-155.
  100. Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F. Advances in the treatment of hemophilia: implications for laboratory testing. Clin Chem. 2019;65(2):254-262.
  101. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT Foundation. Semin Thromb Hemost. 2009;35(8):786-793.
  102. Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost. 2009;35(8):752-759.
  103. Duncan E, Collecutt M, Street A. Nijmegen-Bethesda assay to measure factor VIII inhibitors. Methods Mol Biol. 2013;992:321-333.
  104. Torita S, Suehisa E, Kawasaki T, et al. Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method. Blood Coagul Fibrinolysis. 2011;22(3):185-189.
  105. Favaloro EJ, Bonar R, Kershaw G, et al. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia. 2010;16(4):662-670.
  106. Kershaw GW, Chen LS, Jayakodi D, Dunkley SM. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors. Thromb Res. 2013;132(6):735-741.
  107. Kershaw G. Detection and measurement of factor inhibitors. Methods Mol Biol. 2017;1646:295-304.
  108. Miller CH. Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review. Haemophilia. 2018;24(2):186-197.
  109. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM. Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen- Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012;10(6):1055-1061.
  110. Verbruggen B, Dardikh M, Polenewen R, van Duren C, Meijer P. The factor VIII inhibitor assays can be standardized: results of a workshop. J Thromb Haemost. 2011;9(10):2003-2008.
  111. Batty P, Hart DP, Platton S. Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A. Int J Lab Hematol. 2018; 40: 561-568.
  112. Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia. 2018;24(3):487-491.
  113. Millner AH, Tiefenbacher S, Robinson M, Boesen HT. A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity. Int J Lab Hematol. 2016;38(6):639-647.
  114. Rampersad AG, Boylan B, Miller CH, Shapiro A. Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non- haemophilic patients. Haemophilia. 2018;24(5):807-814.
  115. Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM. Hemophilia Inhibitor Research Study Investigators. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. J Thromb Haemost. 2017;15(10):1971-1976.
  116. de Lima Montalvao SA, Tucunduva AC, de Almeida Sambo AL, De Paula EV, de Souza Medina S, Ozelo MC. Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction. Thromb Res. 2015;136(6):1280-1284.
  117. Miller CH, Rice AS, Boylan B, et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013;11(7):1300-1309.
  118. Lewis KB, Hughes RJ, Epstein MS, et al. Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. PLoS ONE. 2013;8(5):e61120.
  119. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247-251.
  120. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935-1939.
  121. Klintman J, Hillarp A, Berntorp E, Astermark J. Long-term anti- FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol. 2013;163(3):385-392.
  122. Patil R, Chandrakala S, Parihar A, Mohite A, Shetty S. Role of lupus anticoagulants in immediate acting inhibitor positivity in congenital haemophilia A patients. Thromb Res. 2018;172:29-35.
  123. Batty P, Moore GW, Platton S, et al. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thromb Haemost. 2015;114(4):804-811.
  124. Hofbauer CJ, Whelan SF, Hirschler M, et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood. 2015;125(7):1180-1188.
  125. Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. Haemophilia. 2013;19(1):106-112.
  126. Sahud M, Zhukov O, Mo K, Popov J, Dlott J. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies. H aemophilia. 2012;18(5):777-781.
  127. Irigoyen MB, Primiani L, Felippo M, et al. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay. Haemophilia. 2011;17(2):267-274.
  128. Kim SY, Kang SY, Lee WI. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay. Korean J Lab Med. 2010;30(3):260-263.
  129. Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519-2530.
  130. Konkle BA, Stine K, Visweshwar N, et al. Updated follow-up of the Alta study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult patients with severe hemophilia A. Blood. 2019;134(Supplement 1):2060.
  131. Robinson M, George LA, Samelson-Jones BJ, et al. Activity of a FIX-Padua transgene product in commonly used FIX: C one-stage and chromogenic assay systems following PF-06838435 (SPK- 9001) gene delivery. Blood. 2018;132(Supplement 1):2198.
  132. Clinical and Laboratory Standards Institute. CLSI H57-A Protocol for the Evaluation, Validation, and Implementation of Coagulometers. Vol. 28, No. 4. Wayne, PA: Clinical and Laboratory Standards Institute, 2008. https://clsi.org/media/1389/h57a_sample.pdf. Hozzáférés: 2019. szeptember 12.
  133. Gardiner C, Kitchen S, Dauer RJ, Kottke-Marchant K, Adcock DM. Recommendations for evaluation of coagulation analyzers. Lab Hematol. 2006;12(1):32-38.
  134. Jennings I, Kitchen DP, Woods TA, Kitchen S, Walker ID, Preston FE. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia. 2009;15(2):571-577.

TOVÁBBI INFORMÁCIÓ

További kiegészítő információk találhatóak online a További információk részben.